Adjusted for cell proportions: FALSE PR **PNR** PR - PNR IFX IFX IFX T cell activation (I) (LI.M7.1) enriched in T cells (I) (LI.M7.0) -T cell activation (III) (LI.M7.4) -T cell surface signature (LI.S0) enriched in B cells (I) (LI.M47.0) -T cell activation and signaling (LI.M5.1) -T cell activation (II) (LI.M7.3) -T cell differentiation (LI.M14) -T cell differentiation via ITK and PKC (LI.M18) -T cell differentiation (Th2) (LI.M19) enriched in B cells (II) (LI.M47.1) -Direction of effect plasma cells & B cells, immunoglobulins (LI.M156.0) -Down at week 14 enriched in B cells (III) (LI.M47.2) -Not significant B cell surface signature (LI.S2) -Gene module Up at week 14 enriched in NK cells (I) (LI.M7.2) -Effect size (AUC) enriched in B cells (VI) (LI.M69) regulation of antigen presentation and immune response (LI.M5.0) -0.7 enriched in activated dendritic cells/monocytes (LI.M64) -0.8 enriched in myeloid cells and monocytes (LI.M81) -0.9 small GTPase mediated signal transduction (LI.M215) -TBA (LI.M55) blood coagulation (LI.M11.1) platelet activation (II) (LI.M32.1) cell cycle and transcription (LI.M4.0) enriched in monocytes (IV) (LI.M118.0) -Monocyte surface signature (LI.S4) enriched in neutrophils (I) (LI.M37.1) -TLR and inflammatory signaling (LI.M16) immune activation - generic cluster (LI.M37.0) enriched in monocytes (II) (LI.M11.0) -40 -log10(FDR)